disappear
one
patient
classifi
aid
arc
progress
gener
lymphadenopathi
pg
l
asymptomat
asymptomat
individu
arcpgl
patient
equal
distribut
group
aid
patient
found
exclus
group
ii
without
mig
mark
incid
blood
transmiss
viru
drug
addict
transfus
patient
found
group
wherea
group
ii
includ
homosexu
drug
addict
transfus
patient
risk
factor
without
exclud
differ
found
absolut
number
lymphocyt
ratio
serolog
statu
respect
hbv
cmv
ebv
syphili
platelet
group
patient
vs
group
ii
two
patient
group
simultan
chronic
hepat
disord
kidney
graft
none
overt
lymphoma
interestingli
enough
group
patient
simultan
mark
polyclon
hypergammaglobulinemia
wherea
group
ii
abnorm
data
suggest
spontan
b
cell
activ
hiv
patient
may
restrict
monoclon
igg
mainli
earli
phase
infect
appear
link
viral
cofactor
contrast
previou
statement
frequent
observ
drug
addict
transfus
patient
precis
natur
cell
mediat
renal
allograft
reject
human
still
matter
debat
sinc
data
avail
literatur
either
morpholog
obtain
condit
medium
potentiali
modifi
cell
reactiv
hand
definit
reject
highli
variabl
report
order
avoid
obstacl
chosen
studi
concomittantli
phenotyp
function
activ
graft
infiltr
cell
gic
case
welldefin
reject
statu
ie
acut
reject
human
renal
allograft
surgic
remov
kidney
ruptur
day
posttransplant
gic
obtain
mechan
dilacer
without
enzymat
digest
cultur
without
medium
gic
phenotyp
function
studi
parallel
peripher
blood
lymphocyt
pbl
test
specif
donor
cell
gic
consist
major
activ
cell
e
rosett
ia
predomin
phenotyp
cytotox
suppressor
cell
small
proport
b
cell
monocytesmacrophag
also
evidenc
gic
also
abl
prolifer
lectin
allogen
cell
stimuli
strongli
cytotox
toward
specif
donor
target
cell
within
cell
subset
cell
separ
cytofluorometri
display
specif
cytotox
conclus
type
patient
acut
cellular
reject
renal
allograft
highli
complex
phenomenon
involv
strong
cellular
cytotox
solubl
mediat
lymphocyt
activ
aim
studi
investig
develop
specif
suppressor
cell
ts
concomitantli
level
interleukin
ill
iu
secret
peripher
blood
lymphocyt
pbl
renal
transplant
recipi
cyclosporin
cya
treatment
ts
evidenc
mix
recipi
pretranspl
pbl
posttranspl
pbl
stimul
specif
donor
cell
wherea
pbl
cultur
supernat
obtain
spontan
lp
pha
stimul
test
ill
iu
activ
thymidin
incorpor
assay
use
respect
thymocyt
ctll
cell
line
patient
evalu
longitudin
day
posttransplant
reject
result
show
clearli
demonstr
mainten
phase
toler
day
cya
cyapati
associ
low
level
cyaand
secret
cya
iu
increas
group
day
return
low
level
thereaft
reject
disappear
increas
group
far
less
extent
cy
wherea
vari
patient
patient
conclus
transplant
toler
achiev
without
cya
associ
late
develop
low
level
ill
varianc
report
rat
transplant
toler
reject
associ
increas
amount
ill
loss
ts
state
cy
larg
reduc
secret
interleukin
inflammatori
respons
l
jcouderc
f
danon
c
rouzioux
j
p
clauvel
g
saimot
seligmann
elev
level
ig
frequent
pgl
patient
studi
frequenc
oligo
clonal
ig
patient
syndrom
homosexu
men
intraven
drug
user
haemophiliac
heterosexu
male
origin
haiti
central
africa
group
circul
antibodi
lav
present
case
elisa
serum
sampl
test
paragon
electrophoresi
identif
protein
band
perform
immunofix
techniqu
oligoclon
ig
found
case
igg
kappa
igg
lambda
igg
kappa
igg
lambda
polyclon
ig
normal
increas
igghiv
titer
found
greater
elisa
patient
patient
studi
western
blot
analysi
antibodi
sever
hiv
protein
present
followup
period
month
none
patient
develop
malign
andor
opportunist
infect
distribut
igg
subclass
human
immunodefici
viru
hiv
antivir
antibodi
studi
indirect
immunofluoresc
one
hundr
human
sera
sera
collect
asymptomat
carrier
risk
group
patient
la
arc
aid
perform
cell
deriv
molt
line
infect
hiv
viru
half
sera
obtain
risk
group
la
patient
exhibit
hiv
antibodi
subclass
antibodi
restrict
igg
sera
contrast
among
sera
arc
aid
patient
hiv
antibodi
present
subclass
observ
patient
sera
long
observ
cell
line
deriv
line
found
highli
suscept
human
immunodefici
viru
hiv
replic
cytopath
effect
approxim
cell
mostli
giant
cell
aris
virusinduc
cell
fusion
score
fluoresc
use
posit
antihiv
sera
use
acetonefix
cell
fluoresc
local
cytoplasm
cell
membran
uninfect
use
control
use
system
found
sera
patient
aid
risk
aid
posit
sera
also
test
elisa
test
ela
via
diagnost
pasteur
concord
result
obtain
sera
sera
give
discord
result
posit
elisa
neg
posit
radioimmunoprecipit
assay
ripa
neg
gave
non
interpret
result
convers
sera
posit
ripa
neg
elisa
sera
patient
autoimmun
diseas
could
readili
distinguish
give
differ
type
stain
uninfect
infect
cell
studi
demonstr
valu
altern
sensit
specif
test
detect
antihiv
antibodi
previou
studi
describ
decreas
percentag
posit
cell
invers
correl
valu
serum
hcg
observ
decreas
phase
serum
peak
hormon
pregnant
women
week
amenorrhea
hypothes
invers
correl
hcg
cell
exist
increas
concentr
hormon
week
decreas
circul
cell
would
expect
occur
earli
pregnanc
verifi
hypothesi
follow
women
pregnanc
year
old
whose
husband
azoosperm
thu
underw
artifici
insemin
peripher
blood
lymphocyt
subpopul
studi
monoclon
antibodi
radioimmunolog
dosag
hcg
perform
time
ovul
week
week
pregnanc
signific
diminut
popul
observ
earli
first
week
gestat
ascend
phase
hcg
peak
follow
increas
week
descend
phase
hcg
peak
result
favor
vivo
action
hcg
lymphocyt
subset
howev
mechan
action
still
unknown
establish
cytolyt
lymphocyt
ctl
line
clone
specif
facult
intracellular
bacterium
listeria
monocytogen
cell
lyse
bone
marrow
macrophag
infect
monocytogen
infect
mycobacterium
bovi
releas
interferoni
ifni
costimul
bacteri
antigen
antigen
present
cell
adopt
transfer
protect
upon
monocytogen
infect
mice
popul
level
cell
broadli
crossreact
use
limit
dilut
split
cultur
assay
could
identifi
two
differ
type
cytolyt
cell
type
monocytogen
specif
one
show
stringent
restrict
wherea
one
crossreact
clone
type
cell
restrict
ctl
recogn
monocytogen
antigen
context
class
molecul
crossreact
clone
lyse
infect
target
cell
follow
haplotyp
mous
strain
use
experi
differ
also
mi
micro
globulin
loci
henc
ctl
appear
monocytogenesspecif
absenc
appar
mi
microglobulinrestrict
kill
ctl
block
antii
monocytogen
monoclon
antibodi
wherea
monoclon
antibodi
inhibit
cytolysi
find
suggest
cell
receptor
structur
involv
target
cell
recognit
ctl
absenc
appar
restrict
dewild
p
ramon
p
wattr
patient
immunocompromis
subject
transplant
hemopathi
aid
respiratori
distress
variou
pulmonari
diseas
neurolog
disord
viral
pneumonia
involv
viru
research
cell
cultur
direct
identif
immunofluoresc
use
monoclon
antibodi
bronchoalveolar
fluid
lba
obtain
wash
brush
igm
igg
antibodi
evalu
use
elisa
sera
cerebrospin
fluid
lba
sampl
carri
pulmonari
viral
infect
identifi
one
sever
method
lba
examin
twice
immunofluoresc
cmv
herp
simplex
viru
cell
cultur
cmv
herp
simplex
viru
type
anti
cmv
igm
antibodi
anti
herp
varicella
igm
antibodi
signific
increas
anti
cmv
igg
antibodi
direct
examin
lba
viru
research
cultur
previous
report
serolog
investig
never
use
diagnos
viral
infect
respiratori
diseas
combin
use
lba
one
hand
monoclon
antibodi
method
detect
viral
antigen
hand
serolog
find
elisa
special
refer
igm
antibodi
give
abil
provid
clinician
rapid
sensit
specif
diagnost
method
essenti
adequ
evalu
viral
complic
especi
immunocompromis
patient
urolog
nephrolog
centr
mansoura
univers
mansouraegypt
f
elchenawi
moustafa
ghoneim
donor
relat
recipi
estim
total
helper
suppressor
peripher
blood
lymphocyt
use
monoclon
antibodi
ortho
indirect
fluoresc
techniqu
sampl
peripher
blood
lymphocyt
taken
day
monthli
transplant
year
also
episod
reject
recipi
episod
along
time
studi
one
year
transplant
rest
case
show
reject
episod
accompani
increas
helper
suppressor
ratio
time
reject
shortli
recipi
classifi
two
group
accord
type
immunosuppress
treatment
group
take
convent
treatment
group
b
take
cyclosporin
recipi
group
show
reject
episod
case
accompani
increas
helper
suppressor
ratio
recipi
group
b
show
reject
episod
case
accompani
increas
helpersuppressor
ratio
result
demonstr
valu
estim
helper
suppressor
ratio
regular
interv
rise
helpersuppressor
ratio
correl
reject
episod
good
number
case
demonstr
antibodyindepend
kill
coredefect
mutant
rform
minnesota
initi
high
affin
cl
clq
bind
bind
cl
clq
rform
involv
lp
well
outer
membran
protein
omp
bacteria
macrophag
mcp
abl
synthes
clq
detect
membran
determin
cell
abl
differenti
serum
resist
sform
serumsensit
remut
shown
phase
contrastand
electron
microscopi
remut
bound
directli
mcp
wherea
sform
bound
presenc
either
purifi
lp
omp
adhes
block
also
contrast
wild
type
remut
minnesota
typhimurium
induc
guinea
pig
well
mous
tetanu
toxinderiv
fragment
bub
atox
bind
gangliosid
synaptosom
respons
internalis
retrograd
axon
transport
toxin
antibodi
bub
antibub
could
inhibit
tetanu
toxin
activ
investig
immun
statu
toward
tetanu
evalu
tetanu
antitoxin
antibub
individu
elisa
easi
perform
reproduc
intertest
coeffici
variat
intratest
variat
signific
ns
level
sensit
antitoxin
antibub
respect
ivlml
vim
thu
elisa
could
discrimin
protect
protect
peopl
accord
threshold
protect
still
investig
elisa
among
individu
age
year
protect
tetanu
antitoxin
titr
ivlml
ie
male
femal
femal
year
age
antibub
titr
vlml
ns
demonstr
male
versu
femal
p
dramat
variat
accord
age
furthermor
among
individu
antitoxin
titr
ivlml
protect
tetanu
present
antibub
titr
vim
signific
antibub
absenc
tetanu
antitoxin
protect
tetanu
maxplanckinsritut
fur
immunbiologi
stubeweg
freiburg
frg
acquir
resist
intracellular
bacteria
mediat
specif
cell
activ
macrophag
increas
antimicrobi
function
studi
growth
inhibit
intracellular
pathogen
mycobacterium
bovi
tuberculosi
lymphokin
activ
macrophag
periton
macrophag
normal
mice
show
mark
variat
capac
inhibit
growth
mycobacteria
probabl
due
unknown
vivo
stimuli
therefor
use
nine
day
old
bone
marrow
macrophag
obtain
cultiv
serumfre
medium
repres
quiescent
macrophag
popul
macrophag
cultur
live
mycobacteria
four
day
afterward
mycobacteri
number
determin
uptak
determin
coloni
form
unit
stimul
recombin
interferoni
rifni
supernat
antigenstimul
helper
cell
clone
mitogenactiv
normal
cell
growth
bovi
tuberculosi
strain
rv
markedli
reduc
contrast
tuberculosi
strain
middelburg
resist
ifni
induc
macrophag
activ
macrophag
activ
abrog
specif
antiifn
antiserum
parallel
respiratori
burst
activ
bone
marrow
macrophag
investig
lucigenindepend
chemiluminesc
phagocytosi
zymosan
bovi
challeng
zymosan
chemiluminesc
respons
significantli
increas
ifn
activ
macrophag
contrast
bovi
induc
background
chemiluminesc
unstimul
stimul
macrophag
tropism
la
v
ihtl
v
iii
viru
lymphocyt
attribut
specif
interact
viru
molecul
lymphocyt
lymphocyt
tropism
explain
earli
infect
brain
diseas
sinc
also
express
non
cell
line
macrophag
line
variou
b
cell
line
also
suscept
htl
v
iiila
v
infect
wonder
anoth
extra
thymic
express
site
viru
receptor
could
demonstr
brain
topic
express
brain
tissu
analys
sever
anti
monoclon
antibodi
transcript
examin
mean
specif
cdna
probe
northern
blot
analysi
differ
defin
cerebr
area
shown
specif
mrna
found
cerebellum
well
limbic
cortex
immunohistochem
studi
reveal
express
variou
cellular
element
identifi
thu
far
character
cell
tumor
cell
line
fresh
tumor
section
also
analys
express
concomitantli
transcript
express
shown
glioma
cell
line
simultan
express
gfap
could
demonstr
current
studi
investig
infect
cell
viru
univers
konstanz
faculti
biolog
konstanz
frg
h
gmunder
k
keck
human
sera
incub
bovin
serum
albumin
bsa
ovalbumin
ova
submit
gel
filtrat
sephadex
observ
high
molecular
weight
fraction
contain
label
materi
human
sera
test
bound
two
protein
maxim
bind
capac
ngml
bsa
gml
ova
normal
sera
mice
rabbit
cattl
bind
either
two
protein
human
serum
albumin
assumpt
specif
antibodi
respons
bind
protein
confirm
follow
observ
ammonium
sulfat
satur
precipit
ovacontain
fraction
fraction
bound
bsa
antibodi
human
immunoglobulin
togeth
st
aureu
cell
precipit
label
materi
complet
neither
antisera
human
igm
iga
bound
fraction
result
complet
consist
ordinari
igg
antibodi
bind
serum
compon
contrast
bsa
contain
serum
fraction
ovafract
complet
dissoci
n
propion
acid
incomplet
bind
observ
st
aureu
cell
case
autoradiographi
immun
electrophoresi
plate
demonstr
small
part
igg
band
label
conclud
human
sera
contain
antibodi
ova
bsa
may
result
oral
immun
food
compon
contain
two
protein
like
antibodi
belong
igg
class
howev
antibodi
may
domin
sinc
antibodi
subclass
bound
st
aureu
cell
propion
acid
stabl
fraction
may
easili
explain
bind
ova
part
agi
ab
complex
ce
donne
apport
un
element
nouveau
dan
la
physiopathologi
de
la
grossess
conflictair
de
type
rh
laboratoir
dimmunologi
hopit
ch
nicol
tuni
tunisi
appear
cell
mediat
immun
may
import
role
pathogenesi
bd
examin
cell
cell
subset
use
panel
monoclon
antibodi
proport
cell
decreas
concomit
increas
result
abnorm
low
ratio
cell
analys
quantit
tac
dr
antigen
freshli
isol
cell
patient
bd
amount
contain
supernat
hour
phastimul
peripher
blood
lymphocyt
pbl
tac
dr
cell
significantli
increas
p
patient
bd
compar
control
pbl
bd
respond
weakli
pha
con
stimul
control
individu
pbl
obtain
bd
exhibit
higher
uml
product
pbl
control
studi
demonstr
one
hand
cell
activ
vivo
shown
express
tac
dr
antigen
hand
bd
significantli
increas
product
pblpha
stimul
mechan
underli
immunolog
reaction
involv
induct
hyperglycemia
multipl
subdiabetogen
dose
streptozotocin
stz
male
mice
still
obscur
test
stz
act
antigen
cell
vivo
mean
poplit
lymph
node
pln
assay
subcutan
sc
inject
mg
stz
one
hind
footpad
male
recipi
result
weight
increas
drain
pln
mean
pln
index
sem
day
compar
result
obtain
balbc
ksj
recipi
male
femal
mice
respond
similarli
sc
inject
stz
lymphocyt
requir
stzinduc
pln
enlarg
mice
sc
inocul
mg
stz
result
signific
p
pln
weight
increas
mean
pln
index
sem
wherea
athym
counterpart
contrast
complet
fail
mean
pln
index
sem
specif
acceler
secondari
pln
respons
could
induc
subimmunogen
dose
stz
balbc
mice
prime
sc
mg
stz
develop
signific
p
increas
upon
second
sc
inocul
mg
stz
result
maxim
mean
pln
weight
increas
sem
day
sem
day
respect
secondari
pln
respons
ensu
alloxan
anoth
diabetogen
use
second
inject
recipi
prime
solvent
stz
previou
studi
provid
evid
mediat
inflamm
eg
histamin
leukotrien
releas
rat
mast
cell
human
granulocyt
interact
hemolysinproduc
e
coli
strain
report
extend
previou
observ
provid
evid
cellbound
hemolysin
could
releas
cultur
medium
prove
activ
wash
bacteria
e
coli
produc
hemolysin
unlik
hlystrain
induc
high
amount
histamin
releas
rat
mast
cell
led
signific
chemiluminesc
respons
enzym
leukotrien
releas
pmn
bacteri
cultur
supernat
hli
secret
strain
show
similar
result
except
e
coli
hemolysinproduc
secret
strain
investig
role
bacteri
fimbriat
e
coli
msh
mrh
hli
transform
recombin
plasmid
e
coli
strain
express
one
type
agglutinin
fimbria
respect
bacteria
differ
bacteri
adhes
smrh
p
msfimbria
studi
regard
releas
histamin
rat
mast
cell
enzym
newli
gener
oxygen
radic
arachidon
acid
metabolit
mediat
inflamm
data
suggest
role
sfimbria
smrh
factor
induc
potenti
releas
inflammatori
mediat
simultan
presenc
smrh
sfimbria
increas
mediat
releas
compar
smrh
fimstrain
e
coli
msh
mrh
hli
inact
induc
mediat
releas
thu
data
show
defin
bacteria
trigger
cell
mediat
releas
process
may
modul
hostdefens
mechan
serum
resist
shown
base
releas
complex
bacteri
surfac
case
reason
believ
mechan
serum
resist
test
serumresist
strain
e
coli
freshli
isol
blood
cultur
respect
factor
h
cs
bind
incub
pool
normal
human
serum
strain
resist
least
human
serum
use
indirect
innumofluoresc
test
differ
bind
pattern
observ
result
allow
us
divid
strain
three
differ
group
group
character
attach
cs
bacteri
cell
wherea
factor
h
bind
small
amount
group
ii
factor
h
easili
bound
bacteria
cs
detect
bacteria
group
iii
factor
h
shown
result
confirm
observ
measur
consumpt
cs
use
hemolyt
test
group
group
ii
bacteria
consum
compar
amount
wherea
cs
activ
group
bacteria
use
radio
label
complement
compon
result
hemolyt
test
verifi
could
shown
group
bacteria
activ
whole
complement
cascad
membran
attack
complex
gener
releas
supernat
wherea
bacteria
group
ii
complement
activ
interrupt
level
find
therefor
indic
second
mechan
serum
resist
e
coli
clinic
need
hiv
relat
ill
agent
enhanc
immun
function
without
offer
caus
viru
new
target
damag
sodium
diethyldithiocarbam
dtc
thymomimet
drug
uniqu
activ
cell
without
mitogen
activ
basi
vitro
posit
data
pompid
et
al
cancer
re
suppl
initi
uncontrol
pilot
phase
iii
trial
patient
stage
hivrel
ill
given
dtc
mglkg
oral
week
patient
evalu
month
imuthiol
administr
delay
cutan
hypersensit
dch
clearli
improv
patient
shown
multitest
system
institut
merieux
lyon
franc
mean
dch
score
patient
mm
rang
dtc
increas
mm
rang
treatment
proport
number
cell
significantli
p
augment
patient
increas
mean
cell
number
mm
rang
mm
rang
patient
initi
gener
symptom
note
slow
improv
includ
weight
gain
side
effect
observ
doubl
blind
random
trial
ongo
confirm
potenti
use
dtc
immunomodul
patient
hiv
relat
ill
ilaboratoir
dimmunologi
fac
med
pitiesalpetrier
pari
charl
foix
vri
sur
sein
franc
measur
lymphocyt
subset
function
gener
transferrin
receptor
pha
stimul
everi
week
elderli
hospit
long
stay
unit
subject
present
bacteri
infect
major
death
caus
popul
compar
person
present
health
chang
protocol
lower
respiratori
tract
infect
appear
individu
follow
pattern
observ
prior
infect
subject
immunodepress
p
pha
respons
p
infect
occur
immunodepress
worsen
monocyt
also
decreas
sever
infect
paramet
increas
follow
fifteen
day
upper
urinari
tract
infect
notic
individu
immunodepress
could
notic
prior
infect
infect
occurr
well
pha
respons
decreas
increas
ratio
dramat
lower
p
day
later
return
previou
level
pha
respons
still
decreas
pulmonari
kidney
infect
differ
interrelationship
immun
system
better
understand
effect
infect
immun
system
may
permit
possibl
better
treatment
dramat
episod
elderli
lymphoma
cell
nk
cell
activ
might
therefor
predict
valu
patient
high
risk
aid
purpos
investig
evalu
nk
cell
activ
peripher
blood
mononuclear
cell
patient
la
v
ihtl
viii
ill
classic
target
cell
line
sinc
interferon
known
regul
nk
activ
interest
test
vitro
activ
nk
cell
alpha
recombin
interferon
studi
proport
leur
effector
cell
attempt
correl
data
propos
stratif
relat
ill
h
n
haverko
cowork
patient
enter
studi
test
time
diagnosi
treatment
could
interfer
immunolog
function
demonstr
patient
high
risk
aid
nk
cell
activ
diminish
compar
age
sexmatch
normal
individu
although
normal
profil
note
patient
vitro
treatment
interferon
boost
effect
nk
cell
activ
patient
preliminari
analysi
data
suggest
absenc
correl
clinic
stage
paramet
cellular
immun
defici
inserm
uso
cnr
ua
hop
e
herriot
lab
immunol
bioi
pulm
hop
l
f
mornex
g
cordier
j
page
j
f
cordier
j
brune
j
p
revillard
pulmonari
sarcoidosi
character
immun
process
compartiment
within
interstiti
lung
structur
ie
alveoli
ti
alveoli
ti
compris
mostli
lymphocyt
activ
prolifer
respons
mainten
sarcoidosi
alveolar
cell
shown
divid
express
hla
class
ii
antigen
releas
interleukin
investig
express
lung
cell
membran
marker
activ
express
earli
tac
late
dr
antigen
marker
activ
distribut
activ
cell
among
cd
subset
assess
use
flow
cytometr
analysi
monoclon
antibodystain
alveolar
cell
obtain
bronchoalveolar
lavag
patient
pulmonari
sarcoidosi
alveoli
ti
compris
mostli
cell
averag
total
alveolar
cell
vs
macrophag
b
cell
leur
cell
lymphocyt
cd
among
cell
express
dr
antigen
receptor
thu
sarcoidosi
alveoli
ti
character
small
proport
divid
cell
express
earli
activ
marker
inkeep
previou
find
cell
phase
cell
cycl
contrast
among
cell
express
dr
subset
cd
subset
show
cell
activ
restrict
vivo
helperinduc
subset
within
lung
maxplanckinstitut
fiir
immunbiologi
stiibeweg
freiburg
frg
depart
patholog
univers
cambridg
uk
experiment
infect
mice
mycobacteria
use
model
system
character
cell
relev
acquir
resist
tuberculosi
adopt
transfer
experi
found
immun
lymphocyt
recov
mice
infect
bovi
bcg
substrain
phipp
could
protect
mice
infect
virul
tuberculosi
organ
recent
role
cell
subpopul
antibacteri
immun
vivo
could
investig
indirectli
reconstitut
irradi
thymectom
mice
cell
subpopul
select
vitro
gener
monoclon
antibodi
cell
surfac
marker
mous
lymphocyt
elimin
cell
subpopul
vivo
effici
cobbold
et
al
allow
direct
approach
question
evalu
contribut
distinct
cell
subpopul
antimycobacteri
immun
vivo
thymectom
adult
mice
select
residu
peripher
cell
five
week
later
applic
monoclon
antibodi
andor
cell
surfac
molecul
vivo
effici
elimin
proven
function
phenotyp
group
mice
infect
intraven
x
live
tuberculosi
influenc
cell
subpopul
growth
mycobacteria
vivo
determin
three
week
later
highest
bacteri
multipl
found
cell
defici
mice
howev
elimin
cell
also
lead
enhanc
growth
mycobacteria
thu
remov
either
cell
subset
permit
significantli
enhanc
bacteri
growth
presenc
one
cell
subpopul
suffici
establish
effect
antibacteri
immun
conclud
cell
subpopul
necessari
effect
defenc
tuberculosi
cerebr
neocortex
known
modul
immun
system
asymmetr
way
previous
report
larg
ablat
left
cortex
decreas
wherea
symmetr
right
lesion
enhanc
band
cellmedi
respons
howev
anatom
physiolog
studi
show
neocortex
heterogen
structur
thu
specul
differ
aspect
immun
system
could
regul
variou
cortic
area
experi
restrict
neocort
lesion
involv
parietooccipit
lobe
perform
c
hhe
mice
anim
right
lesion
show
depress
mitogeninduc
lymphoprolifer
compar
anim
bilater
lesion
enhanc
antibodi
product
sheep
erythrocyt
left
lesion
appear
modifi
reaction
furthermor
percentag
suppressorcytotox
lymphocyt
depress
anim
bilater
lesion
compar
group
none
lesion
perform
appear
modifi
natur
killer
cell
activ
result
confirm
connect
left
right
cortex
involv
modul
immun
system
indic
immunomodulatori
function
cortex
depend
upon
variou
area
latter
activ
immun
system
well
known
subject
influenc
classic
condit
behaviour
condit
depress
immun
respons
mainli
studi
use
paradigm
tast
avers
condit
develop
ader
cohen
psycho
om
med
accord
paradigm
anim
introduc
pair
present
oral
saccharin
condit
stimulu
cs
inject
immunosuppress
drug
uncondit
stimulu
us
anim
later
reintroduc
cs
alon
show
tast
avers
cs
mark
diminut
immun
reactiv
use
variou
dose
cyclophosphamid
cyclosporin
us
abl
show
tast
avers
condit
immunodepress
independ
phenomenon
effect
condit
observ
presenc
residu
effect
immunosuppress
drug
critic
analysi
experiment
requir
paradigm
lead
us
propos
anoth
methodolog
approach
studi
relationship
condit
immunodepress
absolut
number
lymphocyt
known
import
prognost
paramet
gay
men
infect
hiv
viru
sinc
evalu
cell
mediat
immun
hemophiliac
done
aid
epidem
littl
known
prognost
valu
determin
cell
subset
vitro
lymphocyt
function
hemophiliac
infect
hiv
decemb
start
longitudin
studi
hiv
infect
hemophiliac
patient
develop
aid
five
abl
studi
immunolog
paramet
onset
diseas
belong
group
patient
whose
absolut
count
absolut
count
aid
patient
rang
prior
outbreak
opportunist
infect
none
patient
whose
count
lay
part
examin
two
time
develop
aid
data
support
hypothesi
absolut
count
import
prognost
marker
also
hemophiliac
result
compar
prolif
respons
patient
lymphocyt
lectin
presenc
autoantibodi
assess
sera
male
patient
aid
persist
gener
lymphadenopathi
andor
thrombocytopenia
asymptomat
anti
hiv
antibodi
homosexu
intraven
drug
user
haitian
autoantibodi
detect
use
hemagglutinin
indirect
immunofluoresc
assay
result
neg
anti
thyroglobulin
adren
striat
muscl
intercellular
basement
membran
mitochondri
ribosom
endoplasm
reticulum
antibodi
thyroid
microsom
gastric
pariet
cell
antibodi
present
respect
patient
antinuclear
antibodi
without
antidna
antibodi
one
patient
patient
smooth
muscl
autoantibodi
sma
titer
antiintermedi
filament
type
antivimentin
antikeratin
one
anti
actin
type
presenc
sma
may
reflect
high
incid
viral
infect
patient
conclud
signific
incid
autoantibodi
hiv
infect
patient
div
clinic
immunolog
univers
freiburg
pediatr
univers
hospit
ulm
frg
decemb
june
infant
femal
male
clinic
diagnosi
scid
analys
peripher
blood
lymphocyt
function
prior
immunotherapeut
measur
test
compris
band
nk
cell
marker
iymphoprolif
respons
nk
adcc
activ
target
respect
moreov
infant
test
ada
pnp
activ
whole
blood
infant
subsequ
treat
ident
n
haploident
n
bone
marrow
transplant
bmt
followup
examin
made
infant
still
aliv
ethnic
composit
group
immunolog
classif
regard
ada
activ
presenc
rudimentari
b
nk
cell
compart
present
bstate
scid
patient
assum
percentag
surfac
ig
posit
sig
cell
exceed
ia
cell
iscid
defin
erosett
form
cell
cell
minim
mitogen
respons
nk
cell
activ
monoclon
antibodi
mcab
specif
surfac
antigen
hepat
b
viru
hbv
obtain
immun
balbc
mice
either
hbv
particl
subvir
hbsag
particl
mcab
specif
nucleocapsid
protein
hbv
prepar
use
highli
purifi
liverderiv
hbcag
prepar
purif
procedur
immunogen
shown
preserv
morpholog
immunolog
properti
presenc
specif
ab
detect
indirect
ria
use
nativ
hbv
core
particl
solid
phase
antigen
antimous
immunoglobulin
tracer
second
antibodi
hybridoma
clone
screen
polypeptid
specif
western
blot
use
viru
core
protein
antigen
probe
mcab
react
blot
env
protein
reactiv
abolish
vs
proteas
treatment
hbv
tryptic
hydrolysi
mcab
shown
recogn
residu
ctermin
end
mcab
show
reactiv
vssensit
presl
epitop
local
kd
envprotein
kd
larg
env
protein
also
present
hbv
prepar
mcab
react
core
particl
ria
human
polyclon
circul
ab
bound
major
core
protein
encod
c
gene
hbv
dna
anoth
mcab
react
also
nativ
hbcag
recogn
minor
larg
coreassoci
polypeptid
specif
mcab
x
antigen
determin
may
consid
conclus
model
structur
organ
hbv
particl
propos
c
pfeiffer
nain
gemsa
macrophag
shown
particip
host
defens
viru
infect
limit
viral
replic
littl
known
whether
macrophag
would
also
respond
infecti
viru
particl
releas
prostanoid
mediat
may
induc
inflamm
may
modul
immun
reactiv
present
studi
resid
periton
macrophag
mice
vitro
infect
vesicular
stomat
viru
vsv
herp
simplex
viru
type
hsv
repres
prostanoid
determin
radioimmunoassay
prostaglandin
metabolit
prostacyclin
pgf
incub
macrophag
x
ml
hour
variou
concentr
vsv
dosedepend
stimul
prostanoid
synthesi
found
multipl
infect
mol
x
x
vsvml
occur
without
appar
cell
damag
higher
vsv
concentr
mol
higher
dosedepend
caus
cell
death
parallel
reduc
prostanoid
synthesi
contrast
hsv
slightli
stimul
prostanoid
synthesi
low
mol
wherea
higher
mol
prostanoid
releas
strongli
inhibit
level
lower
produc
un
infect
control
cell
gener
found
virus
induct
suppress
prostanoid
synthesi
detect
incub
period
longer
hour
data
show
viral
bacteri
product
may
stimul
prostanoid
synthesi
macrophag
howev
appear
depend
infect
viru
threshold
concentr
may
rapidli
reach
incapacit
releas
inflammatori
immunomodulatori
prostanoid
macrophag
previous
report
astrocyt
induc
express
class
ii
ia
antigen
expos
yinterferon
ifni
astrocyt
function
antigen
present
cell
may
therefor
playa
role
immunosurveil
central
nervou
system
recent
ifni
independ
induct
ia
rat
astrocyt
corona
viru
demonstr
vitro
therefor
studi
surfac
express
ia
follow
persist
infect
astrocyt
neurotrop
bornadiseas
viru
bdv
cell
deriv
newborn
lewi
rat
brain
cultur
four
week
infect
bdv
astrocyt
natur
viral
infect
brain
monolay
cell
establish
immunofluoresc
peroxidaseantiperoxidas
techniqu
found
posit
glial
fibrillari
acid
protein
gfap
bdvspecif
antigen
infect
astrocyt
express
laantigen
surfac
howev
treatment
recombin
ifni
concanavalina
supernat
bdvinfect
astrocyt
well
noninfect
control
induc
express
detect
amount
surfac
laantigen
cell
also
posit
bdv
specif
cell
surfac
antigen
cellular
enzym
link
immunosorb
assay
elisa
use
polyclon
monoclon
antibodi
find
suggest
induct
la
astrocyt
gener
consequ
viral
infect
relev
pathogenesi
viral
neurolog
diseas
remain
establish
compar
repartit
ratio
blood
donor
drug
addict
popul
antilay
hbcposit
neg
serolog
studi
lymphocyt
subpopul
perform
whole
blood
sampl
cytofluorometri
blood
lymphocyt
label
mous
monoclon
antibodi
coulter
studi
epic
c
cell
sorter
method
fast
accur
optic
techniqu
precis
appreci
studi
ten
donor
ten
time
coeffici
variat
antibodi
alway
less
comparison
result
popul
show
hard
correl
antilay
seroposit
invers
ratio
differ
found
la
v
ab
neg
donor
la
v
ab
neg
drug
addict
whatev
hbv
serolog
may
xlink
sever
combin
immunodefici
diseas
recess
inherit
disord
character
complet
absenc
lymphocyt
lethal
absenc
bone
marrow
transplant
underli
intrins
molecular
defect
impair
cell
differenti
defin
use
genet
linkag
analys
determin
subchromosomalloc
xlscid
first
step
identifi
primari
defect
diseas
fourteen
fragment
length
polymorph
marker
x
chromosom
test
examin
meiotic
event
aris
four
famili
risk
xlscid
herein
report
preliminari
result
show
signific
linkag
xlscm
locu
defin
polymorph
dna
probe
probe
assign
xq
region
lod
score
e
linkag
data
strongli
suggest
xlscid
locu
lie
proxim
part
long
arm
x
chromosom
strike
note
xlink
agammaglobulinemia
locat
region
x
chromosom
p
kwan
et
al
find
may
playa
signific
role
prenat
diagnosi
carrier
state
detect
character
possibl
new
gene
famili
human
x
chromosom
involv
ontogeni
b
lymphocyt
abt
immunologi
und
transfusionsmedizin
abt
abdominalund
transplantationschirurgi
abt
thorax
herzund
gefafkhirurgi
abt
klinisch
chemi
medizinisch
hochschul
hannov
krankenhau
nordstadt
hannov
frg
presenc
extens
earli
lymphocyt
infiltr
skin
lesion
suggest
lymphocyt
could
involv
pathogenesi
present
immunohistolog
retrospect
studi
focus
pattern
composit
cellular
infiltr
lesion
skin
biopsi
specimen
patient
clv
extens
fibrinoid
necros
vessel
wall
patient
hemorrhag
drug
erupt
hde
biopsi
specimen
unalt
skin
control
examin
stain
serial
cryostat
section
monoclon
antibodi
mab
cell
surfac
antigen
pant
helper
suppressor
pmn
b
cell
receptor
hladr
monocytesmacrophag
use
immunoenzym
techniqu
pattern
infiltr
classifi
diffus
mainli
perivascular
rel
percentag
respect
cell
type
estim
semiquantit
two
investig
hde
pattern
lymphocyt
diffus
contrast
predominantli
perivascular
distribut
cl
v
latter
case
diffus
scatter
infiltr
outsid
perivascular
area
consist
pmn
monocyt
perivascular
infiltr
clv
contain
mainli
helper
cell
median
ratio
clv
contrast
hde
control
observ
follow
median
rel
frequenc
perivascular
area
clv
hde
normal
skin
respect
pmn
monocytesmacrophag
activ
posit
lymphocyt
lymphocyt
normal
skin
total
number
stain
cell
alway
low
clv
monocytesmacrophag
frequent
spread
along
basement
membran
affect
vessel
wall
hde
control
find
indic
identif
cellular
infiltr
mab
especi
ratio
may
help
differenti
clv
hde
ratio
increas
sever
macroscop
lesion
cl
v
use
recombin
protein
deriv
envgen
human
immunodefici
viru
hiv
serodiagnosi
hivinfect
compar
perform
convent
confirmatori
assay
immunofluoresc
western
blot
elisa
obtain
recombin
clone
envgen
deriv
kb
bgl
ii
fragment
hivdna
two
express
plasmid
transform
e
coli
produc
kd
fusion
protein
kd
polypeptid
pcl
react
patient
sera
western
blot
patient
sera
test
western
blot
prepar
recombin
materi
result
compar
obtain
commerci
elisa
convent
western
blot
purifi
viru
immunofluoresc
sera
gave
clearcut
posit
result
test
sera
nonreact
confirmatori
assay
posit
initi
screen
elisa
sera
discrep
result
convent
test
recombin
western
blot
produc
correct
diagnosi
good
perform
recombin
western
blot
procedur
develop
purifi
recombin
materi
bacteriallys
order
abl
use
elisa
gesellschaft
fur
immunologi
societ
fran
ais
dlmmunologi
inserm
u
hopit
tenon
pari
franc
e
h
g
van
leer
p
moullier
p
ronco
p
verroust
addit
major
histocompat
complex
class
molecul
number
initi
lymphocyt
defin
antigen
demonstr
kidney
variou
speci
order
complement
studi
decid
analyz
reciproc
express
lymphocyt
six
renal
brush
border
antigen
primarili
defin
monoclon
antibodi
mab
rais
rat
bb
demonstr
kd
protein
gp
synthes
proxim
tubul
cell
glomeruli
found
surfac
b
cell
antigen
includ
kd
protein
involv
heymann
autolog
immun
complex
nephritisa
model
epimembran
glomerulonephr
detect
surfac
lymphocyt
solid
phase
immunodeplet
techniqu
gp
identifi
dipeptidyl
peptidas
iv
dpp
iv
immunochem
studi
indic
protein
identifi
immunoprecipit
bb
thymocyt
membran
comigr
sdspage
thu
exclud
crossreact
quantit
bind
analysi
show
number
antigen
site
order
magnitud
thymocyt
spleen
bonemarrow
lymphocyt
well
two
line
preb
lama
pret
restc
cell
consider
lower
highli
differenti
helper
cell
line
roser
similar
studi
perform
us
rabbit
mous
suggest
dpp
iv
similar
distribut
renal
bb
glomeruli
thymocyt
wherea
studi
perform
other
human
lymphocyt
suggest
dpp
iv
activ
may
present
cell
immunochem
character
howev
carri
find
contribut
analysi
antigen
make
lymphocyt
surfac
furthermor
sinc
previous
shown
kd
antigen
could
serv
target
format
short
live
immun
glomerular
deposit
may
also
valu
studi
kinet
immun
deposit
immunopatholog
role
protein
close
resembl
gp
demonstr
mous
rabbit
suggest
mman
blood
sampl
fiftyf
hiv
seroposit
patient
refer
institut
pasteur
hospit
analyz
employ
antibodi
latter
two
antibodi
report
recogn
subpopul
within
posit
popul
postul
defin
helperinduc
subset
lymphocyt
wherea
identifi
induc
suppressor
cytotox
subpopul
antibodi
react
ts
b
lymphocyt
flow
cytometri
simultan
dual
immunofluoresc
perform
antibodi
directli
conjug
fitc
coupl
phycoerythrin
seroposit
patient
divid
four
group
seroposit
carrier
spc
lymphadenopathi
patient
lan
aid
relat
complex
arc
aid
patient
categori
absolut
valu
cd
posit
